The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.
One of the most effective ways to reduce overtreatment of prostate cancer is to limit its detection in men with low-risk disease. Although many data are currently missing, we foresee a future with reduced prostate-specific antigen (PSA) testing in men selected through baseline PSA values or genetic predisposition. Then selective biopsy using multiparametric magnetic resonance imaging and longitudinal biomarkers will play a role.